3D Microscopic profiling of pathological tau spreading in optically cleared brains
Jan
R.
Detrez1*,
Hervé
Maurin2,
Kristof
Van Kolen2,
Roland
Willems2,
Julien
Colombelli3,
Benoit
Lechat4,
Bart
Roucourt5,
Fred
Van Leuven4,
Sarah
Baatout6,
Peter
Larsen2,
Rony
Nuydens2,
Jean-Pierre
Timmermans1 and
Winnok
H.
De Vos1
-
1
University of Antwerp, Belgium
-
2
Janssen Research & Development, Belgium
-
3
Institute for Research in Biomedicine, Spain
-
4
Laboratory for Experimental Mouse Genetics, Belgium
-
5
reMYND NV, Belgium
-
6
Belgian Nuclear Research Centre, Belgium
Layman Abstract
Converging evidence suggest that the progression of Alzheimer’s disease is characterized by the accumulation and spreading of pathological proteins throughout the brain. Investigating this 3D spreading process in mouse models is however limited to 2D tissue sections with conventional microscopic methods. We have developed an innovative approach that is able to render a mouse brain transparent, allowing us to capture this spreading process in intact mouse brains. We have used this technology to acquire a detailed description of the disease progression in 3 mouse models, and showed that we can inhibit the spreading process using therapeutic antibodies.
Abstract
Alzheimer’s disease (AD) is characterised by the progressive deposition of beta-amyloid plaques and hyperphosphorylated tau in the brain. Both tau, and to a lesser extent amyloid, oligomers progressively spread via defined patterns throughout the brain and are proposed to act as seeds for ensuing protein aggregation. However, transgenic mouse models for tauopathies show tau spreading patterns that do not resemble those observed in human patients. Moreover, previous histological examination was done based on brain sections, which is labour-intensive and complicates downstream procedures, such as brain atlas mapping. To study the development of tau pathology in a controlled manner, we inoculated pathogenic tau fibrils – either synthetically produced (K18) or isolated from AD patient brains (ePHF) - in the CA1 region of a tauopathy mouse model (Tau.P301L) and after set time points we monitored the distribution of hyperphosphorylated tau in toto using iDISCO+ clearing and light sheet microscopy [1]. While the pathological tau load in non-inoculated Tau.P301L mice only became detectable at 6 months of age, we found that inoculation of 3 months-old Tau-P301L mice with K18 fibrils significantly expedited tau pathology, with hyperphosphorylated tau-positive neurons emerging as early as 7 days post injection (DPI), in both the ispi- and contralateral hemisphere. With a strong enrichment in the hippocampus, cortex and thalamus, the tauopathy pattern also vastly differed from that of the non-inoculated counterparts, where hyperphosphorylated tau predominantly accumulated in the brainstem. The K18-inoculation induced spreading pattern followed anatomical connections that directly emanated from the injection site, feeding the theory of cellular transmission through anatomically connected networks. Inoculation with ePHF resulted in a slower progression, with negligible somatic tau pathology at 28 DPI, but a pronounced hyperphosphorylated tau load at 84 DPI that spatially resembled the K18 inoculation pattern. We further demonstrate that tau pathology can be lowered after intracranial and systemic administration of a microtubule-binding domain targeted antibody in combination with K18 seeding. The combination of targeted seeding and in toto staging of hyperphosphorylated tau offers a unique approach to assess regional vulnerability and connectivity. This in turn will contribute to a better understanding of pathological progression and will allow evaluating the potential of therapeutic interventions aimed at halting or reversing the spreading process.
Figure 1: In toto Imaging of hyperphosphorylated tau in P301L mice after K18 inoculation. A. Workflow for microscopic interrogation of hyperphospho-rylated tau in intact mouse brain. B. 3D rendering of AT8 pathology in K18-injected Tau.P301L mouse brains over time. C. Heatmap plots are used to visualise the AT8 load in brain subregions over time. P-Values within the tiles indicate significant increases compared to buffer-injected controls.
References
1. Renier, N., Adams, E. L., Kirst, C., Wu, Z., Azevedo, R., Kohl, J., … Tessier-Lavigne, M. (2016). Mapping of Brain Activity by Automated Volume Analysis of Immediate Early Genes. Cell, 165(7), 1789–1802. http://doi.org/10.1016/j.cell.2016.05.007
Keywords:
tau,
Alzheimer’s disease,
Tau.P301L,
whole brain imaging,
Light-sheet microscopy
Conference:
Belgian Brain Congress 2018 — Belgian Brain Council, LIEGE, Belgium, 19 Oct - 19 Oct, 2018.
Presentation Type:
e-posters
Topic:
NOVEL STRATEGIES FOR NEUROLOGICAL AND MENTAL DISORDERS: SCIENTIFIC BASIS AND VALUE FOR PATIENT-CENTERED CARE
Citation:
Detrez
JR,
Maurin
H,
Van Kolen
K,
Willems
R,
Colombelli
J,
Lechat
B,
Roucourt
B,
Van Leuven
F,
Baatout
S,
Larsen
P,
Nuydens
R,
Timmermans
J and
De Vos
WH
(2019). 3D Microscopic profiling of pathological tau spreading in optically cleared brains.
Front. Neurosci.
Conference Abstract:
Belgian Brain Congress 2018 — Belgian Brain Council.
doi: 10.3389/conf.fnins.2018.95.00023
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
30 Jul 2018;
Published Online:
17 Jan 2019.
*
Correspondence:
Mr. Jan R Detrez, University of Antwerp, Antwerp, Belgium, detrez.jan@gmail.com